07:00 , Aug 4, 2014 |  BC Week In Review  |  Clinical News

iCo-007: Phase II data

Top-line data from the physician-sponsored, U.S. Phase II iDEAL trial in 187 Type I or II diabetics with DME showed that all intravitreal injections of 350 and 700 Ug iCo-007 alone and 350 Ug iCo-007...
07:00 , Jun 24, 2013 |  BC Week In Review  |  Clinical News

iCo-007: Completed Phase II enrollment

iCo said investigators completed enrollment in the U.S. Phase II iDEAL trial to evaluate intravitreal injections of 350 and 700 µg iCo-007 alone and in combination with laser photocoagulation or ranibizumab in about 208 patients....
07:00 , Aug 22, 2011 |  BC Week In Review  |  Clinical News

iCo-007: Phase II started

iCo said investigators began the U.S. Phase II iDEAL trial to evaluate intravitreal injections of iCo-007 alone and in combination with laser photocoagulation or ranibizumab. iCo has exclusive, worldwide rights to iCo-007 to treat eye...
07:00 , May 24, 2010 |  BC Week In Review  |  Clinical News

iCo-007: Final Phase I data

Final data from an open-label, dose-escalation, U.S. Phase I trial in 15 patients showed that single intravitreal injections of iCo-007 reduced excess retinal thickness by 40%. Additionally, iCo-007 led to stable or improved vision in...
08:00 , Dec 21, 2009 |  BC Week In Review  |  Clinical News

iCo-007: Preliminary Phase I data

Preliminary data from an open-label, dose-escalation, U.S. Phase I trial in 15 patients showed that single intravitreal injections of 110, 350, 700 or 1,000 µg iCo-007 were well tolerated with no drug-related serious adverse events....
07:00 , Jul 13, 2009 |  BC Week In Review  |  Clinical News

iCo-007: Phase I ongoing

iCo said a safety evaluation committee has recommended the continuation of an open-label, dose-escalation Phase I trial of single intravitreal doses of iCo-007 into a fourth and final cohort. iCo received exclusive, worldwide rights to...
07:00 , Sep 29, 2008 |  BC Week In Review  |  Clinical News

iCo-007: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 15 to 30 patients with diffuse diabetic macular edema (DME) had a third cohort of patients approved by the trial's Safety Evaluation Committee. No serious adverse events...
07:00 , Oct 15, 2007 |  BC Week In Review  |  Clinical News

iCo-007: Phase I started

iCo began an open-label, dose-escalation Phase I trial of intravitreal iCo-007 in 15-30 patients, which triggered a $1.25 million milestone payment to ISIS under a 2005 deal that granted iCo exclusive rights to the compound...
08:00 , Jan 29, 2007 |  BC Week In Review  |  Clinical News

iCo-007: Phase I start

This half, iCo will begin a dose-escalation Phase I trial. In 2005, ISIS granted iCo exclusive rights to the compound to treat eye diseases caused by choroidal neovascularization (see BioCentury, Aug. 29, 2005). iCo Therapeutics...
08:00 , Jan 8, 2007 |  BC Week In Review  |  Clinical News

iCo-007: IND submitted

iCo submitted an IND to FDA for iCo-007 to treat eye diseases including age-related macular degeneration (AMD) and diabetic retinopathy. In 2005, ISIS granted iCo exclusive rights to the compound to treat eye diseases caused...